Patients with a variety of malignancies have seen better outcomes from anticancer immunotherapies like immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells. However, due to the primary or adaptive / acquired immune resistance mechanisms of the tumor microenvironment, the majority of patients either do not initially respond or fail to show lasting responses. These numerous suppressive programs can use a variety of cell types to strengthen the stability of patients with ostensibly the same cancer type and are different between them. As a result, the overall advantages of monotherapies are still modest. Comprehensive tumor profiling is now made possible by cutting-edge technologies, and it can be used to define the intrinsic and extrinsic pathways of primary and / or acquired immune resistance in tumor cells, also known as features or feature sets of immunity resistance to current therapies. We suggest that immune resistance archetypes, which are made up of five feature sets that include well-known immune response mechanisms, can be used to classify cancers. Clinicians may be able to prioritize targeted therapy combinations for specific patients in order to increase overall efficacy and outcomes. Archetypes of resistance may inform new therapeutic strategies that simultaneously address multiple cell axes and / or suppressive mechanisms.